Trends in Biologic Therapies for Rheumatoid Arthritis: Results from a Survey of Payers and Providers

摘要

BackgroundAdvances in therapies for rheumatoid arthritis (RA), particularly biologics, have transformed the treatment paradigm for RA. However, the associated costs of these therapies result in a significant economic burden on the healthcare system. As a chronic disease requiring lifelong treatment, most health plans now position RA drugs as a high-priority therapeutic category.